ERJ Open Research · 2024 · 12 citations · 19 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyInflammationPulmonologyPulmonary InflammationRespiratory DiseaseRespiratory MedicineDipeptidyl PeptidasesEosinophil CountExacerbation PhenotypingLung Function DeclineLung Function TestingPost Hoc AnalysisPost Hoc Subgroup Analysis
Introduction Bronchiectasis is a chronic inflammatory airway disease. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), reduces pulmonary inflammation by preventing the activation of neutrophil serine proteases. In the phase II WILLOW trial, brensocatib prolonged time to first exacerbation in patients with bronchiectasis. In this post hoc analysis we compare clinical outcomes in patients from WILLOW according to baseline disease characteristics. Methods Adults with bronchiectasis treated with brensocatib (10 or 25 mg) or placebo once daily were analysed by baseline Bronchiectasis Severity Index (BSI) score (≤4 (mild), 5–8 (moderate), or ≥9 (severe)), exacerbation history (2 or ≥3 in the previous year), blood eosinophil count (<300 cells per µL or ≥300 cells per µL), long-term macrolide use (≥6 months; no or yes) and Pseudomonas aeruginosa culture at screening (negative or positive). End-points were time to first exacerbation, annualised exacerbation rate, change in lung function from baseline, and safety. All patients who received brensocatib were pooled and compared with placebo. Results Treatment with brensocatib versus placebo was associated with a longer time to first exacerbation (hazard ratio (95% confidence interval), BSI: ≤4, 0.28 (0.08–0.96); 5–8, 0.75 (0.35–1.60); ≥9, 0.61 (0.35–1.04); prior exacerbations: 2, 0.56 (0.34–0.90); ≥3, 0.71 (0.32–1.59); blood eosinophils per µL: <300, 0.66 (0.42–1.06); ≥300, 0.49 (0.20–1.20); long-term macrolide use: no, 0.60 (0.38–0.94); yes, 0.60 (0.25–1.45); P. aeruginosa culture: negative, 0.54 (0.32–0.92); positive, 0.68 (0.37–1.27)). Safety results were similar across subgroups. Discussion Patients treated with brensocatib had a numerically longer time to first exacerbation and reduced annualised rate of exacerbation versus placebo across all key baseline disease characteristics.
19
James D. Chalmers, Kelly Moffitt, Guillermo Suárez-Cuartín et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 414 citations · Full text
Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
James D. Chalmers, Charles Haworth, Mark L. Metersky et al. · New England Journal of Medicine · 2020 · 353 citations